中恒集团业绩预亏股价震荡，子公司整合与药品获批引关注

Group 1 - The core viewpoint of the news is that Zhongheng Group (600252) anticipates a net profit loss of 250 million to 450 million yuan for the fiscal year 2025, primarily due to a decline in core business, impairment provisions, and losses from non-operating income [1] - The company’s subsidiary, Hunan Kangyuan Pharmaceutical Co., Ltd., received approval for a supplementary application for sodium lactate Ringer's injection, which may enhance its market competitiveness [1] Group 2 - On February 10, 2026, Zhongheng Group announced the absorption merger of its wholly-owned subsidiary Nanning Shuangqian by its holding subsidiary Shuangqian Industry, aimed at improving operational efficiency, reducing management costs, and optimizing resource allocation [2] - Following the merger, Nanning Shuangqian's legal status will be canceled, and its related assets and liabilities will be inherited by Shuangqian Industry, with no significant asset restructuring or payment required [2] Group 3 - Over the past week (February 7 to 13, 2026), Zhongheng Group's stock price has shown a downward trend, closing at 2.55 yuan on February 13, down 1.16% from 2.60 yuan on February 9, with a price fluctuation of 3.10% [3] - Trading volume peaked at 87.37 million yuan on February 12 but decreased to 52.19 million yuan on February 13, with a net inflow of 4.3975 million yuan on that day, indicating the stock is trading between a resistance level of 2.68 yuan and a support level of 2.52 yuan [3] - The overall performance of Zhongheng Group is weaker than the pharmaceutical and biotechnology sector, which saw a decline of 0.64% during the same period [3] Group 4 - Institutional interest in Zhongheng Group is low, with a neutral sentiment prevailing in the market; there have been no institutional surveys, and 100% of institutional ratings are neutral, with a fund holding ratio of only 0.01% [4] - Profit forecasts indicate an earnings per share of -0.11 yuan for 2024, reflecting a year-on-year decline of 547.14%, highlighting fundamental pressures on the company [4] - No recent targeted research reports have been published by brokerage firms regarding Zhongheng Group [4]